MYCOPLASMA TREATMENT PROTOCOL
GARTH NICOLSON, PhD.,#63
Institute for molecular medicine.org, immed.org
Intracellular organism without cell wall
Smaller than bacteria but larger than virus
Chronic opportunistic infection, some cases life long
Potential for infection causing:
Chronic fatigue
Neuropathy
Foggy brain
Muscle aches/pain
GI Distress
Coinfection with lyme or virus 70% of time
Common for miscarriage and infertility, is sexually transmitted, to offspring
Ovarian cancer, endometriosis, interstitial cystitis; by causing mutations in cancer cells to be more malignant
Potential for immune suppression
ALS, causal and accelerates NEURODEGERERATIVE DXZ, tx reversals are known if tx early
Autoimmunity,
Leaky gut
Many are carriers
Mycoplasma can reek havoc in pts
Diagnosis is difficult, try Company: Clongen, Maryland
Mycoplasma pneumonia easier to detect than M. fermentens (Gulf War Syndrome-from vaccine)
Resides in the mouth and upper respiratory system
Oxidative free radical damage of mitochondria (inner membrane) and cell transport & function)
May be contracted by airborne means
TREATMENT
Different for different people
Tx first with several courses of ABX then supplements once infection is contained
HBO or Ozone for maintenance or relapse
Membrane Lipid replacement therapy for cell membrane / fluid mosaic model
Glycerophosolipids
NTfactor lipids (exogenous therapy)
Chemical/fume removal by lipid replacement
Tx hydrophobic mold toxins with lipid replacement
Resolves pain and fatigue, GI leaky gut, nerve injury,
Not just phosphotydilcholine, but balanced with phosphotidylglycerol precursor for cardiolipin made in mitochondria, special ratio of fats & precursors (NTFactor Lipids ) orthomolecular no soy
NT Factor lipids: (colorless/tasteless) Nutritional Therapeutics NTI, new york/ Allergy research /Nutracology /iherb
Sick 4-6 g/d, if healthy 2g/d; for chelation 3g/d, 8 wks to see change
